[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340146-105":59,"doc-detail-340146-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","arrest-and-attack-microtubule-targeting-agents-and-oncolytic-viruses-employ-complementary-mechanisms-to-enhance-anti-tumor-therapy-efficacy","Arrest and Attack - Microtubule-Targeting Agents and Oncolytic Viruses Employ Complementary Mechanisms to Enhance Anti-Tumor Therapy Efficacy","","Oncolytic viruses (OVs) serve as promising cancer immunotherapy agents by preferentially infecting and killing tumor cells to stimulate antitumor immunity. Limited clinical use partly reflects constrained efficacy when used as monotherapies. Enhancing OV potency often relies on combining OVs with complementary modalities that exploit distinct tumor vulnerabilities. Microtubule-targeting agents (MTAs) disrupt microtubule dynamics, trigger cell-cycle arrest, and promote mitotic cell death, potentially improving outcomes. However, off-target effects and acquired resistance may restrict overall benefit. Combined OV–MTA therapy may increase OV infection and immunogenic cell death while lowering resistance likelihood. This review introduces OVs and MTAs, details their molecular activity features in cancer cells, and summarizes studies and clinical trials testing the combination.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/arrest-and-attack-microtubule-targeting-agents-and-oncolytic-viruses-employ-complementary-mechanisms-to-enhance-anti-tumor-therapy-efficacy/340146/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/arrest-and-attack-microtubule-targeting-agents-and-oncolytic-viruses-employ-complementary-mechanisms-to-enhance-anti-tumor-therapy-efficacy/340146.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are oncolytic viruses considered promising for cancer immunotherapy?","Question",{"text":112,"@type":113},"Oncolytic viruses preferentially infect and kill tumor cells, stimulating antitumor immunity. Their tumor selectivity and ability to drive immune responses support their therapeutic potential.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limits the clinical efficacy of oncolytic viruses when used alone?",{"text":117,"@type":113},"Their efficacy as monotherapies is restricted in part, motivating strategies to improve therapeutic potency through combination with other modalities.",{"name":119,"@type":110,"acceptedAnswer":120},"How can combining microtubule-targeting agents with oncolytic viruses enhance anti-tumor therapy?",{"text":121,"@type":113},"MTAs perturb microtubule dynamics, induce cell-cycle arrest, and cause mitotic cell death. When combined with OVs, the therapy may increase OV infection and immunogenic cell death while decreasing the probability of acquired resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340146,1790211935,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Review  \nArrest and Attack: Microtubule-Targeting Agents and Oncolytic Viruses Employ Complementary Mechanisms to Enhance Anti-Tumor Therapy Efficacy  \nSucheta De and Marcelo Ehrlich *  \nCitation: De, S.; Ehrlich, M. Arrest  \nand Attack: Microtubule-Targeting Agents and Oncolytic Viruses Employ Complementary Mechanisms to Enhance Anti-Tumor Therapy Efficacy. Genes 2024, 15, 1193 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)genes15091193  \nAcademic Editor: Gael Roue  \nReceived: 18 July 2024  \nRevised: 25 August 2024  \nAccepted: 4 September 2024  \nPublished: 11 September 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nShmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel; [suchetade@mail.tau.ac.il](suchetade@mail.tau.ac.il)  \n* [Correspondence: marceloe@tauex.tau.ac.il](Correspondence: marceloe@tauex.tau.ac.il)  \nAbstract: Oncolytic viruses (OVs) are promising cancer immunotherapy agents that stimulate antitumor immunity through the preferential infection and killing of tumor cells. OVs are currently under limited clinical usage, due in part to their restricted efficacy as monotherapies. Current efforts for enhancement of the therapeutic potency of OVs involve their combination with other therapy modalities, aiming at the concomitant exploitation of complementary tumor weaknesses. In this context, microtubule-targeting agents (MTAs) pose as an enticing option, as they perturb microtubule dynamics and function, induce cell-cycle arrest, and cause mitotic cell death. MTAs induce therapeutic benefit through cancer-cell-autonomous and non-cell-autonomous mechanismsand are a main component of the standard of care for different malignancies. However, off-target effects and acquired resistance involving distinct cellular and molecular mechanisms may limit the overall efficacy of MTA-based therapy. When combined, OVs and MTAs may enhance therapeutic efficacy through increases in OV infection and immunogenic cell death and a decreased probability of acquired resistance. In this review, we introduce OVs and MTAs, describe molecular features of their activity in cancer cells, and discuss studies and clinical trials in which the combination has been tested.  \nKeywords: oncolytic virus; microtubule-targeting agents; JNK; combination therapy  \n1. Introduction  \nResistance to single-agent therapies remains a major challenge in cancer therapy. Combination therapies allow for the concomitant targeting of multiple hallmarks of cancer [1,2] and diminish the probability of acquired resistance, but they may also compound undesired side effects. The remarkable and diverse arsenal of therapy strategies and agents that have already been developed generates a daunting number of possible combinations. Moreover, to benefit from the untapped potential of such therapy combinations, a thorough understanding of the molecular mechanisms of action of different therapy modalities and the underpinnings of acquired resistance to such therapies is required. Given the predicted scale and complexity of such data and the marked degree of heterogeneity exhibited by different tumors [3,4], the harnessing of the full potential of combination therapies is expected to require artificial intelligence-based analyses. Furthermore, this convolved scenario also generates complexities for the design of clinical trials aimed at probing the efficacy of such combinations [5,6] . In these contexts, the differences in the susceptibility of distinct tumors to different OVs, and the plurality of modes by which OVs target tumors, are expected to further ","cbCaidFKZEhW4qLq","https://ap.wps.com/l/cbCaidFKZEhW4qLq","pdf",805292,18,"English","# Introduction\n## Challenges of single-agent therapy resistance\n## Rationale for combination therapies and mechanistic understanding\n# The Combination Factors: Oncolytic Viruses and Microtubule-Targeting Agents\n## Oncolytic viruses and their exploitation of the cancer-cell context","[{\"question\":\"Why are oncolytic viruses considered promising for cancer immunotherapy?\",\"answer\":\"Oncolytic viruses preferentially infect and kill tumor cells, stimulating antitumor immunity. Their tumor selectivity and ability to drive immune responses support their therapeutic potential.\"},{\"question\":\"What limits the clinical efficacy of oncolytic viruses when used alone?\",\"answer\":\"Their efficacy as monotherapies is restricted in part, motivating strategies to improve therapeutic potency through combination with other modalities.\"},{\"question\":\"How can combining microtubule-targeting agents with oncolytic viruses enhance anti-tumor therapy?\",\"answer\":\"MTAs perturb microtubule dynamics, induce cell-cycle arrest, and cause mitotic cell death. When combined with OVs, the therapy may increase OV infection and immunogenic cell death while decreasing the probability of acquired resistance.\"}]","Arrest and Attack - Microtubule-Targeting Agents and Oncolytic Viruses Employ Complementary Mechanisms to Enhance Anti-Tumor Therapy Efficacy | PDF",1790034495,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d166495838fe3cbcbca9800e7343173.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7562d96d192e91e4c7dbb4b0c439638c.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f29f0af2e7279cf039ccc922a1bb5457.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b74a2170ece6ec02ad4fedc7035db747.webp",980,1385]